Author:
Zamboni William C.,Ramanathan Ramesh K.,McLeod Howard L.,Mani Sridhar,Potter Douglas M.,Strychor Sandra,Maruca Lauren J.,King Cristi R.,Jung Laura L.,Parise Robert A.,Egorin Merrill J.,Davis Todd A.,Marsh Sharon
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference45 articles.
1. Zamboni WC, Bowman LC, Tan M, et al (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454–460
2. Gupta E, Luo F, Lallo A, et al (2000) The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). Anticancer Res 20:1013–1016
3. Drengler RL, Kuhn JG, Schaaf LJ, et al (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685–696
4. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6:2685–2689
5. Kruijtzer CM, Beijnen JH, Rosing H, et al (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943–2950
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献